European Archives - Page 1304 of 1369 - European Medical Journal

SABRINA: Phase 3 study comparing subcutaneous and intravenous rituximab in follicular lymphoma

An update on the safety results of the phase 3 SABRINA study, which is comparing subcutaneous and intravenous rituximab in the maintenance setting of patients with follicular lymphoma.

Subgroup analysis of the MCL-002 (SPRINT) trial of lenalidomide in relapsed/refractory MCL

At the 20th Congress of the European Hematology Association (EHA), Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, discusses the…

Ongoing studies by the German CLL study group (GCLLSG)

At the 20th Congress of the European Hematology Association (EHA), Barbara Eichhorst, MD, of the University of Cologne, Cologne, Germany, discusses…

HELIOS: Phase 3 trial of ibrutinib in previously treated CLL/SLL

At the 20th Congress of the European Hematology Association (EHA), Paula Cramer, MD, of the University Hospital Cologne, Cologne, Germany, discusses the…

EMJ

STELARA® Receives European Commission Approval for Treatment of Adolescents with Moderate-To-Severe Psoriasis in Europe

Beerse, Belgium, 29 June 2015 – Janssen-Cilag International NV (“Janssen”) announced today that the European Commission (EC) has approved STELARA®…

EMJ

Animation Demonstrating Implantation of the CARILLON Device

Treatment of Secondary Mitral Regurgitation via Percutaneous Annuloplasty

EMJ

Video of Patient Case Showing Real-Time Implantation of the CARILLON Device

Treatment of Secondary Mitral Regurgitation via Percutaneous Annuloplasty: Video of Patient Case Showing Real-Time Implantation of the CARILLON Device.

EMJ

Studies Confirm Regorafenib Benefit in Pre-Treated Metastatic Colorectal Cancer

BARCELONA-LUGANO, 3 July 2015 – The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated…

EMJ

Patients with Lowest BMI Have Shortest Survival in Pooled Analysis of Bevacizumab in Metastatic Colorectal Cancer

BARCELONA-LUGANO, 1 July 2015 – Patients with the lowest body mass index (BMI) had the shortest overall survival in an analysis of bevacizumab studies

EMJ

SENRI Trial Opens Window to Evaluate NK1 Antagonists for Emesis Prevention in Oxaliplatin Chemotherapy

BARCELONA-LUGANO, 1 July 2015 – The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin…